$5.29 Billion Worldwide Biosimulation Industry to 2030 – Identify Growth Segments for Investment – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biosimulation Global Market Report 2021: COVID-19 Implications and Growth” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global biosimulation market.

This report focuses on biosimulation market which is experiencing strong growth. The report gives a guide to the biosimulation market which will be shaping and changing our lives over the next ten years and beyond, including the market’s response to the challenge of the global pandemic.

The global biosimulation market is expected to grow from $2.71 billion in 2020 to $3.17 billion in 2021 at a compound annual growth rate (CAGR) of 17.1%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $5.29 billion in 2025 at a CAGR of 13.7%.

Companies Mentioned

• Certara
• Dassault Systemes
• Schrodinger Inc.
• Simulations Plus Inc.
• Rhenovia Pharma
• Insilico Biotechnology AG
• Genedata AG
• Entelos Inc.
• Physiomics plc
• Rosa & Co. LLC.
• In silico biosciences
• INOSIM Software
• LeadInvent Technologies
• Nuventra Pharma
• Archimedes

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The biosimulation market consists of sales of biosimulation software and services by entities (organizations, sole traders, and partnerships) that are engaged in garnering a better understanding of biological processes using computer simulations. Biosimulation is a mathematical simulation process that uses computers to replicate biological processes and systems. The aim of biosimulation is a model-based prediction of the dynamics and behavior of biological systems.

The main types of products in the biosimulation market are software and services. The biosimulation software provides software for molecular modeling and simulation, pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation, toxicity prediction software, physiologically based pharmacokinetic modeling, and simulation (PBPK) modeling and simulation, trial design software, and others. It is used in drug development, drug discovery, and others and implemented in various verticals such as pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, academic research institutions, others.

North America was the largest region in the biosimulation market in 2020. The Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and AfricaMiddle East, and Africa.

Product innovation is an emerging trend in the biosimulation market. Several companies operating in the biosimulation sector are focused on developing new and advanced solutions for biosimulation. For instance, in January 2021, Insilico Biotechnology AG, a Germany-based company providing predictive solutions for the Bioeconomy launched new software called the Insilico Selector. With the help of the Insilico Selector, it is possible to use micro-scale data for the creation of an accurate selection of high-performing cell clones.

In April 2020, Simulations Plus Inc., a US-based company engaged in providing simulation and modeling software for pharmaceutical development and discovery acquired Lixoft for $16.5 million. With the acquisition of Lixoft, Simulations Plus expands modeling software offerings and plans to broaden the company’s presence in Europe. Lixoft is a France-based company engaged in providing modeling and simulation software for advanced model-based drug development.

The surge in healthcare expenditure worldwide is expected to support the biosimulation market over the forecast period. Increasing healthcare spending is likely to provide more expenditure on the development of drugs which in turn, will drive the revenues generated from the biosimulation solutions. Biosimulation software is currently being used in the development of drugs to mimic diseases. With the help of the biosimulation software, virtual clinical trials can be conducted for new developing pharmaceutical drugs using computers running disease simulations. According to the U.S. Centers for Medicare & Medicaid Services, US healthcare spending increased 4.6% in 2019, reaching $3.8 trillion or $11,582 per person, contributing a share of 17.7% of the nation’s GDP. Therefore, the surge in healthcare expenditure drives the growth of the biosimulation market.

For more information about this report visit https://www.researchandmarkets.com/r/9hu2h9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900